<p>Genetic testing for specific alleles is often recommended based on an individual’s ancestry. However, the frequency of pathogenic and pharmacogenomic alleles across different Hispanic groups has not been well characterized, and existing guidelines often fail to recognize the geographic and ancestral diversity within these populations. Here analyzing data from 6,011 individuals from the nationwide Mexican Biobank, we show that Mexican individuals have striking regional differences in biomedically relevant allele frequencies, shaped both by their overall admixture proportions, but also by the local Indigenous ancestral groups contributing to their genome (for example, Nahua in central Mexico, Zapotec in the South or Maya in the Yucatan peninsula). We found ancestry-specific patterns with clinical implications that could not have been detected without a local ancestry-informed approach, including variants affecting fentanyl (rs2242480) and statin (rs4149056) metabolism, examples particularly relevant to the epidemiology of Hispanic populations. This analysis framework could inform genetic testing guidelines across the Americas. We are making available the results for 42,769 biomedically relevant genotyped variants through MexVar, a user-friendly platform designed to improve access to genomic data for the scientific community and support genetic analyses for populations of Mexican descent worldwide.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Clinical genetic variation across Hispanic populations in the Mexican Biobank

  • Carmina Barberena-Jonas,
  • Santiago G. Medina-Muñoz,
  • Viankail Cedillo-Castelán,
  • Tania Sepúlveda-Morales,
  • Claudia Gonzaga-Jáuregui,
  • Carlos Aguilar-Salinas,
  • Carmina Barberena-Jonas,
  • Sergio Canizales-Quintero,
  • Luis Pablo Cruz-Hervert,
  • Guadalupe Delgado-Sánchez,
  • Elizabeth Ferreira-Guerrero,
  • Leticia Ferreyra-Reyes,
  • Cecilia Gutiérrez-López,
  • Juan Eugenio Hernández-Avila,
  • Alicia Huerta-Chagoya,
  • Luis Juárez-Figueroa,
  • Pablo Kuri-Morales,
  • Eduardo Lazcano-Ponce,
  • Carlos Magis-Rodríguez,
  • Norma Mongua-Rodríguez,
  • Hortensia Moreno-Macías,
  • María de Jesús Ortega-Estrada,
  • María José Palma-Martínez,
  • Consuelo Dayzú Quinto-Cortés,
  • Rosario Rodríguez-Guillén,
  • María Luisa Ordóñez-Sánchez,
  • Elsa Sarti-Gutiérrez,
  • Karla Sandoval,
  • Jaime Sepúlveda-Amor,
  • Mashaal Sohail,
  • Roberto Tapia-Conyer,
  • María Teresa Tusié-Luna,
  • José Luis Valdespino-Gómez,
  • Norma Téllez-Vázquez,
  • Oscar Velázquez-Monroy,
  • Manuel Velázquez-Meza,
  • Lourdes García-García,
  • Alexander G. Ioannidis,
  • Andrés Moreno-Estrada

摘要

Genetic testing for specific alleles is often recommended based on an individual’s ancestry. However, the frequency of pathogenic and pharmacogenomic alleles across different Hispanic groups has not been well characterized, and existing guidelines often fail to recognize the geographic and ancestral diversity within these populations. Here analyzing data from 6,011 individuals from the nationwide Mexican Biobank, we show that Mexican individuals have striking regional differences in biomedically relevant allele frequencies, shaped both by their overall admixture proportions, but also by the local Indigenous ancestral groups contributing to their genome (for example, Nahua in central Mexico, Zapotec in the South or Maya in the Yucatan peninsula). We found ancestry-specific patterns with clinical implications that could not have been detected without a local ancestry-informed approach, including variants affecting fentanyl (rs2242480) and statin (rs4149056) metabolism, examples particularly relevant to the epidemiology of Hispanic populations. This analysis framework could inform genetic testing guidelines across the Americas. We are making available the results for 42,769 biomedically relevant genotyped variants through MexVar, a user-friendly platform designed to improve access to genomic data for the scientific community and support genetic analyses for populations of Mexican descent worldwide.